explore -WSS

explore

author：comprehensive 2025-10-02 13:01:39 - browse：14592

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： 'Revelatory' study finds a smoking impact that remains after quitting

WSS

Key House Republican on health care plans exit from Congress

Beware the threat of staffing cuts at the CDC

Liz Cheney makes 1st public comment since Trump's election interference indictments

Hilary may become 1st tropical storm to make landfall in California in 84 years

What should King Charles tell the public about his cancer?

Senators start work on Medicare physician payment reform

entertainment

explore

hotspot

Medicare details structure of new drug price negotiation program

Biden report: The neurospychology of memory and aging

Jerome Adams on the need for new antivirals for Covid

Hilary may become 1st tropical storm to make landfall in California in 84 years

As demand for Covid shots wanes, Moderna seeks its next success

How digital tools helped lower hypertension in marginalized patients

Hepatitis C has a cure — but many Americans still lack access to it

ProMED sees offers of support, but its future remains unclear

Guidelines to prevent youth baseball injuries need more muscle

KalVista pill reduced swelling 'attacks' caused by genetic disease

focus

Patient advocates sound warning on FDA proposal on salt intake

PhRMA lawsuit over Medicare drug price negotiation tossed

Industry veterans launch new biotech VC with $310M

Living with Hashimoto's and celiac disease, and med school, too

The pain doctors face in trying to build their families

ProMED sees offers of support, but its future remains unclear

Wikipedia

Wikipedia

entertainment

focus